Evidence map›Paper›PMID 24740373›Full record

ArticlePloS one2014

Preparation, characterization, and in vitro cytotoxicity evaluation of a novel anti-tuberculosis reconstruction implant.

JunFeng Dong, ShengMin Zhang, Jun Ma, HaoMing Liu, YingYing Du, YongHui Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. [Research progress on antibacterial properties of porous medical implant materials].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

JunFeng DongAdvanced Biomaterials and Tissue Engineering Center, Huazhong University of Science and Technology, Wuhan, P.R. China; Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, P.R. China.
ShengMin ZhangAdvanced Biomaterials and Tissue Engineering Center, Huazhong University of Science and Technology, Wuhan, P.R. China; Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, P.R. China.
Jun MaAdvanced Biomaterials and Tissue Engineering Center, Huazhong University of Science and Technology, Wuhan, P.R. China; Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, P.R. China.
HaoMing LiuAdvanced Biomaterials and Tissue Engineering Center, Huazhong University of Science and Technology, Wuhan, P.R. China.
YingYing DuAdvanced Biomaterials and Tissue Engineering Center, Huazhong University of Science and Technology, Wuhan, P.R. China.
YongHui LiuAdvanced Biomaterials and Tissue Engineering Center, Huazhong University of Science and Technology, Wuhan, P.R. China.
Huazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReconstruction materials currently used in clinical for osteoarticular tuberculosis (TB) are unsatisfactory due to a variety of reasons. Rifampicin (RFP) is a well-known and highly effective first-line anti-tuberculosis (anti-TB) drug. Poly-DL-lactide (PDLLA) and nano-hydroxyapatite (nHA) are two promising materials that have been used both for orthopedic reconstruction and as carriers for drug release. In this study we report the development of a novel anti-TB implant for osteoarticular TB reconstruction using a combination of RFP, PDLLA and nHA.

methodsRFP, PDLLA and nHA were used as starting materials to produce a novel anti-TB activity implant by the solvent evaporation method. After manufacture, the implant was characterized and its biodegradation and drug release profile were tested. The in vitro cytotoxicity of the implant was also evaluated in pre-osteoblast MC3T3-E1 cells using multiple methodologies.

resultsA RFP/PDLLA/nHA composite was successfully synthesized using the solvent evaporation method. The composite has a loose and porous structure with evenly distributed pores. The production process was steady and no chemical reaction occurred as proved by Fourier Transform Infrared Spectroscopy (FTIR) and X-Ray Diffraction (XRD). Meanwhile, the composite blocks degraded and released drug for at least 12 weeks. Evaluation of in vitro cytotoxicity in MC3T3-E1 cells verified that the synthesized composite blocks did not affect cell growth and proliferation.

conclusionIt is feasible to manufacture a novel bioactive anti-TB RFP/PDLLA/nHA composite by the solvent evaporation method. The composite blocks showed appropriate properties such as degradation, drug release and biosafety to MC3T3-E1 cells. In conclusion, the novel composite blocks may have great potential for clinical applications in repairing bone defects caused by osteoarticular TB.

Indexed as

Drug ImplantsAnimalsAntitubercular AgentsCell LineCell SurvivalDrug CompoundingDurapatiteMiceMicroscopy, Electron, ScanningNanocompositesOsteoblastsPolyestersPorosityRifampinSpectroscopy, Fourier Transform InfraredTuberculosis, OsteoarticularAntitubercular AgentsDrug ImplantsDurapatitePolyesterspoly(lactide)Rifampin

Identifiers

PMID24740373
PMCPMC3989261
OpenAlexW2068468670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.